UNIVERSITY OF ZURICH Patients who survive a cerebral hemorrhage may suffer delayed severe brain damage caused by free hemoglobin, which comes from red blood cells and damages neurons. Researchers at the University of Zurich and the UniversityHospital Zurich have now discovered a protective protein in the body called haptoglobin, which prevents this effect. Bleeding in the narrow space between the inner and middle meninges...
Post
Fat accumulations in airways of obese people detected for first time
By Rich Haridy | October 20, 2019 A novel study has for the first time detected significant accumulations of fatty tissue in airway walls of obese and overweight people. The new research suggests these fat accumulations could explain why overweight individuals are at higher risk of respiratory disease and asthma. “Being overweight or obese has already been linked to having asthma or having worse asthma symptoms,” explains Peter Noble,...
Post
New CRISPR tool has the potential to correct almost all disease-causing DNA glitches, scientists report
By SHARON BEGLEY | OCTOBER 21, 2019 A new form of the genome-editing tool CRISPR-Cas9 appears to significantly expand the range of diseases that could be treated with the technology, by enabling scientists to precisely change any of DNA’s four “letters” into any other and insert or delete any stretch of DNA — all more...
Post
Research improves understanding of mechanism of atrial fibrillation
by Baylor College of Medicine Atrial fibrillation is the most common heart arrhythmia in humans. This condition increases the risk of heart failure, stroke, dementia and death, and current treatments have suboptimal efficacy and carry side effects. Looking to identify clues that might lead to better treatments, a group headed by researchers at Baylor College...
Post
First-ever US clinical trial of engineered iPSC-derived cell therapy for blood cancer
by University of Minnesota Medical School A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer (NK) cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia (AML) and B-cell lymphoma. The...
Post
Phoenix-based company believes it has discovered major breakthrough in Alzheimer’s treatment
By Linda Williams | Published 8 hours ago | Special Reports | FOX 10 Phoenix PHOENIX – Alzheimer’s disease robs millions of people of their memory and their lives, and even after years of research, there’s still no cure. A Phoenix-based company thinks it may have discovered a treatment that stops, even reverses the process....
Post
In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval
By MATTHEW HERPER @matthewherper OCTOBER 22, 2019 In a shocking reversal, Biogen (BIIB) on Tuesday said that it would resurrect an Alzheimer’s drug that the company previously said had failed and will ask the Food and Drug Administration to approve it. The company said a “new analysis of larger dataset” showed that the drug, aducanumab,...
Post
Novel study documents marked slowdown of cell division rates in old age
Clearer understanding of lower cell replication rates in old age may have implications for preventing cancer and slowing aging JOHNS HOPKINS MEDICINE In a novel study comparing healthy cells from people in their 20s with cells from people in their 80s, researchers at the Johns Hopkins Kimmel Cancer Center say they have documented that cell...
Post
New way to wrap liquid drops could improve drug delivery
UNIVERSITY OF WATERLOO Researchers have developed a faster, cheaper way to coat liquid medication, an invention that could improve how drugs are delivered in the body. The new encapsulation technology, developed by engineers at the University of Waterloo, uses gravity and other natural forces to wrap drops as they fall through a thin layer of...
Post
New treatment may reverse celiac disease
New technology may be applicable to other autoimmune diseases and allergies NORTHWESTERN UNIVERSITY CHICAGO — Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to...